45 related articles for article (PubMed ID: 16507327)
21. Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer.
Vansteenkiste J; Canon JL; Riska H; Pirker R; Peterson P; John W; Mali P; Lahn M
Invest New Drugs; 2005 Jun; 23(3):263-9. PubMed ID: 15868384
[TBL] [Abstract][Full Text] [Related]
22. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer.
Paz-Ares L; Douillard JY; Koralewski P; Manegold C; Smit EF; Reyes JM; Chang GC; John WJ; Peterson PM; Obasaju CK; Lahn M; Gandara DR
J Clin Oncol; 2006 Mar; 24(9):1428-34. PubMed ID: 16549837
[TBL] [Abstract][Full Text] [Related]
23. A randomized phase II trial using two different treatment schedules of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer.
Masters GA; Argiris AE; Hahn EA; Beck JT; Rausch PG; Ye Z; Monberg MJ; Bloss LP; Curiel RE; Obasaju CK
J Thorac Oncol; 2006 Jan; 1(1):19-24. PubMed ID: 17409822
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable non-small cell lung cancer.
Abratt RP; Lee JS; Han JY; Tsai CM; Boyer M; Mok T; Kim SW; Lee JS; Brnabic AJ; Reece WH; Lehnert M
J Thorac Oncol; 2006 Feb; 1(2):135-40. PubMed ID: 17409842
[TBL] [Abstract][Full Text] [Related]
25. Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer GFPC 99-01 study (Groupe français de pneumo-cancérologie).
Thomas P; Robinet G; Gouva S; Fournel P; Léna H; Le Caer H; Perol M; Berard H; Bombaron P; Vergnenegre A; Kleisbauer JP;
Lung Cancer; 2006 Jan; 51(1):105-14. PubMed ID: 16310886
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer.
Ritch P; Rudin CM; Bitran JD; Edelman MJ; Makalinao A; Irwin D; Lilenbaum R; Peterson P; John WJ
Lung Cancer; 2006 May; 52(2):173-80. PubMed ID: 16507327
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer.
Chiappori A; Simon G; Williams C; Haura E; Rocha-Lima C; Wagner H; Bepler G; Antonia S
Oncology; 2005; 68(4-6):382-90. PubMed ID: 16020967
[TBL] [Abstract][Full Text] [Related]
28. Gemcitabine/carboplatin in advanced non-small cell lung cancer.
Zatloukal P; Petruzelka L
Lung Cancer; 2002 Nov; 38 Suppl 2():S33-6. PubMed ID: 12431827
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of single-agent gemcitabine in advanced non-small cell lung cancer: a review.
Hansen HH; Sørensen JB
Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-38-S7-41. PubMed ID: 9194478
[TBL] [Abstract][Full Text] [Related]
30. Past, present, and future of gemcitabine and carboplatin regimens in advanced non-small cell lung cancer.
Edelman MJ
Lung Cancer; 2002 Nov; 38 Suppl 2():S37-43. PubMed ID: 12431828
[TBL] [Abstract][Full Text] [Related]
31. Gemcitabine (Gemzar) in non-small cell lung cancer.
Manegold C
Expert Rev Anticancer Ther; 2004 Jun; 4(3):345-60. PubMed ID: 15161434
[TBL] [Abstract][Full Text] [Related]
32. Gemcitabine: symptomatic benefit in advanced non-small cell lung cancer.
Thatcher N; Jayson G; Bradley B; Ranson M; Anderson H
Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-6-S8-12. PubMed ID: 9207309
[TBL] [Abstract][Full Text] [Related]
33. [Advances of drug resistance marker of gemcitabine for non-small cell lung cancer].
Chen Y; Qian X; Liu B
Zhongguo Fei Ai Za Zhi; 2011 May; 14(5):421-8. PubMed ID: 21569648
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
